UnitedHealth's Triple Guidance Hike: A Buy Signal?

UnitedHealth Group (UNH) has raised its full-year earnings guidance for the third time this year, demonstrating that its turnaround is gaining momentum. The company now expects adjusted earnings per share (EPS) of at least $20.50 for 2026, up from its initial forecast of $17.75 in January.

The latest increase follows a strong third-quarter earnings report on Oct. 13, which showed significant improvements in its Optum Health segment. Operating earnings for Optum Health surged to $735 million from just $41 million a year earlier, with operating margins expanding to 3.2% from 0.2%.

Management has been simplifying operations, strengthening leadership, and refocusing on core U.S. healthcare. It has also exited certain international businesses and restructured to better align with competitive advantages.

Optum, the company's healthcare services and technology arm, is becoming a key growth driver. It provides pharmacy services, healthcare technology, and direct patient care, diversifying revenue beyond insurance premiums. Management plans to invest nearly $1.5 billion in AI initiatives in 2026 to improve productivity and healthcare navigation.

Looking ahead, UnitedHealth's 2027 earnings growth target starts at the low end of its 13% to 16% long-term range. Based on this, adjusted EPS could reach $29.60 to $32 by 2029, implying a stock price of $444 to $672 depending on the P/E multiple applied.

The repeated guidance raises are a clear signal that UnitedHealth's operational improvements are real and accelerating. After two years of setbacks, including rising medical costs and Medicare Advantage pressures, the company is now delivering stronger-than-expected results.

Optum's recovery is particularly important because it provides a high-margin, diversified revenue stream that complements the insurance business. The surge in Optum Health's operating earnings shows that management's cost-control measures and strategic focus are paying off.

With a forward P/E of about 17, UNH trades roughly in line with its historical average and the broader market. If earnings grow at the midpoint of management's target range (14.5% annually), EPS could reach $30.80 by 2029, and applying an 18 P/E multiple (similar to today's) would value the stock at $554, representing about 40% upside from recent prices near $398.

However, risks remain. Regulatory scrutiny over Medicare Advantage practices, rising medical costs, and changes in government reimbursement could pressure results. But the third guidance increase suggests the turnaround is gaining traction, and the next three years could be rewarding if earnings continue to climb.